Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Pfizer Adds Warning to Revatio Label on Off-Label PAH Use in Children

Washington Drug Letter

Sept. 10, 2012 | Vol. 44 No. 36

Pfizer Adds Warning to Revatio Label on Off-Label PAH Use in Children

Pfizer and the FDA are warning against off-label use of the company’s Revatio in children up to 17 years old with pulmonary arterial hypertension (PAH).

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Hydrocodone Decision Delay Reflects Enforcement, Access Tensions FDA Rejects Endo’s Petition to Deny Generics of Opana ER House Committee Investigates FDA Official’s Sudden Departure Report Pokes Holes in FDA Celexa Dose Warning

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.